Responsiveness of motor and nonmotor symptoms of Parkinson disease to dopaminergic therapy

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 1, 2010, Pages 57-61

  Stacy, Mark A ^a   Murck, Harald ^b   Kroenke, Kurt ^c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine; Dyskinesia; Motor fluctuations; Nonmotor; Somatization; Wearing off

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT;

ANXIETY; ARTICLE; DRUG RESPONSE; HUMAN; MAJOR CLINICAL STUDY; MOOD CHANGE; MOTOR DYSFUNCTION; MUSCLE CRAMP; MUSCLE STIFFNESS; OUTCOME ASSESSMENT; PAIN; PANIC; PARKINSON DISEASE; SYMPTOMATOLOGY; THINKING IMPAIRMENT; TREMOR;

ACTIVITIES OF DAILY LIVING; BEHAVIORAL SYMPTOMS; CARBIDOPA; DISABILITY EVALUATION; DOPAMINE AGENTS; FEMALE; HUMANS; LEVODOPA; MALE; MOTOR ACTIVITY; OUTCOME ASSESSMENT (HEALTH CARE); PARKINSON DISEASE; QUESTIONNAIRES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 73649090347     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2009.09.023     Document Type: Article

References (47)

1. Adler C.H. Relevance of motor complications in Parkinson's disease. Neurology 58 (2002) S51-S56
2. Aggarwal V.R., McBeth J., Zakrzewska J.M., et al. The epidemiology of chronic syndromes that are frequently unexplained: do they have common associated factors?. Int J Epidemiol 35 (2006) 468-476
3. Agid Y. Parkinson's disease: pathophysiology. Lancet 337 (1991) 1321-1324
4. American Psychiatric Association: Somatoform disorders. TR., in Diagnostic and statistical manual of mental disorders. Edited by American Psychiatric Association. Washington, DC, 2000, pp 485-492.
5. Becker C., Jick S.S., and Meier C.R. Use of antihypertensives and the risk of Parkinson disease. Neurology 70 (2008) 1438-1444
6. Black K.J., Hershey T., Hartlein J.M., et al. Levodopa challenge neuroimaging of levodopa-related mood fluctuations in Parkinson's disease. Neuropsychopharmacology 30 (2005) 590-601
7. Brefel-Courbon C., Payoux P., Thalamas C., et al. Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Mov Disord 20 (2005) 1557-1563
8. Chaudhuri K.R., Yates L., and Martinez-Martin P. The non-motor symptom complex of Parkinson's disease: a comprehensive assessment is essential. Curr Neurol Neurosci Rep 5 (2005) 275-283
9. Colosimo C., and De Michele M. Motor fluctuations in Parkinson's disease: pathophysiology and treatment. Eur J Neurol 6 (1999) 1-21
10. Fung V.S., Herawati L., and Wan Y. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone. Mov Disord 24 (2009) 25-31
11. Goetz C.G., Leurgans S., Pappert E.J., et al. Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology 57 (2001) 2078-2082
12. Gunal D.I., Nurichalichi K., Tuncer N., et al. The clinical profile of nonmotor fluctuations in Parkinson's disease patients. Can J Neurol Sci 29 (2002) 61-64
13. Gupta S., Vincent J.L., and Frank B. Pramipexole: augmentation in the treatment of depressive symptoms. CNS Spectr 11 (2006) 172-175
14. Hagelberg N., Martikainen I., Mansikka H., et al. Dopamine D2 receptor binding in the human brain is associated with the response to painful stimulation and pain modulatory capacity. Pain 99 (2002) 273
15. Hillen M.E., and Sage J.I. Nonmotor fluctuations in patients with Parkinson's disease. Neurology 47 (1996) 1180-1183
16. Holman A.J., and Myers R.R. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 52 (2005) 2495-2505
17. Hughes A.J., Ben Shlomo Y., Daniel S.E., et al. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 42 (1992) 1142-1146
18. Katon W., Lin E.H., and Kroenke K. The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry 29 (2007) 147-155
19. Koerts J., Leenders K.L., Koning M., et al. Striatal dopaminergic activity (FDOPA-PET) associated with cognitive items of a depression scale (MADRS) in Parkinson's disease. Eur J Neurosci 25 (2007) 3132-3136
20. Kroenke K. The interface between physical and psychological symptoms. Prim Care Companion J Clin Psychiatry 5 suppl 7 (2003) 11-18
21. Kroenke K. Efficacy of treatment for somatoform disorders: a review of randomized controlled trials. Psychosom Med 69 (2007) 881-888
22. Kroenke K. Somatoform disorders and recent diagnostic controversies. Psychiatr Clin North Am 30 (2007) 593-619
23. Kroenke K., and Rosmalen J.G. Symptoms, syndromes, and the value of psychiatric diagnostics in patients who have functional somatic disorders. Med Clin North Am 90 (2006) 603-626
24. Kroenke K., Spitzer R.L., and Williams J.B. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med 64 (2002) 258-266
25. Kupfer D.J., and Frank E. Placebo in clinical trials for depression: complexity and necessity. JAMA 287 (2002) 1853-1854
26. Lemke M.R., Brecht H.M., Koester J., et al. Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci 17 (2005) 214-220
27. Löwe B, Wahl I, Rose M, et al. A 4-item measure of depression and anxiety: Validation and standardization of the Patient Health Questionnaire-4 (PHQ-4) in the general population. J Affect Disord in press. doi:10.1016/j.jad.2009.06.019.
28. Marsden C.D., and Parkes J.D. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1 (1976) 292-296
29. Menza M.A., Sage J., Marshall E., et al. Mood changes and "on-off" phenomena in Parkinson's disease. Mov Disord 5 (1990) 148-151
30. Rief W., and Broadbent E. Explaining medically unexplained symptoms-models and mechanisms. Clin Psychol Rev 27 (2007) 821-841
31. Schestatsky P., Kumru H., Valls-Sole J., et al. Neurophysiologic study of central pain in patients with Parkinson disease. Neurology 69 (2007) 2162-2169
32. Schrag A., and Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 123 Pt 11 (2000) 2297-2305
33. Sha M.C., Callahan C.M., Counsell S.R., et al. Physical symptoms as a predictor of health care use and mortality among older adults. Am J Med 118 (2005) 301-306
34. Shulman L.M., Taback R.L., Rabinstein A.A., et al. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 8 (2002) 193-197
35. Slaughter J.R., Slaughter K.A., Nichols D., et al. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 13 (2001) 187-196
36. Stacy M., Bowron A., Guttman M., et al. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord 20 (2005) 726-733
37. Stacy M., Hauser R., Oertel W., et al. End-of-dose wearing off in Parkinson disease: a 9-question survey assessment. Clin Neuropharmacol 29 (2006) 312-321
38. Stacy M.A., Murphy J.M., Greeley D.R., et al. The sensitivity and specificity of the 9-item Wearing-off Questionnaire. Parkinsonism Relat Disord 14 (2008) 205-212
39. Stocchi F. Prevention and treatment of motor fluctuations. Parkinsonism Relat Disord 9 Suppl 2 (2003) S73-S81
40. Sullivan K.L., Ward C.L., Hauser R.A., et al. Prevalence and treatment of non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 13 (2007) 545
41. The Global Parkinson's Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord 17 (2002) 60-67
42. Truong D.D., Bhidayasiri R., and Wolters E. Management of non-motor symptoms in advanced Parkinson disease. J Neurol Sci 266 (2008) 216-228
43. Turner J.A., Deyo R.A., Loeser J.D., et al. The importance of placebo effects in pain treatment and research. JAMA 271 (1994) 1609-1614
44. Tylee A., Gastpar M., Lepine J.P., et al. DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. DEPRES Steering Committee. Int Clin Psychopharmacol 14 (1999) 139-151
45. Veazey C., Aki S.O., Cook K.F., et al. Prevalence and treatment of depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 17 (2005) 310-323
46. Witjas T., Kaphan E., Azulay J.P., et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 59 (2002) 408-413
47. Ziemssen T., and Reichmann H. Non-motor dysfunction in Parkinson's disease. Parkinsonism Relat Disord 13 (2007) 323-332